Get the Stockscreener App
86.04
1.90%
-1.67
Dexcom Inc stock is traded at $86.04, with a volume of 3.50M.
It is down -1.90% in the last 24 hours and down -1.49% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
See More
Previous Close:
$87.71
Open:
$87.925
24h Volume:
3.50M
Relative Volume:
1.00
Market Cap:
$32.47B
Revenue:
$4.82B
Net Income/Loss:
$930.40M
P/E Ratio:
36.80
EPS:
2.3381
Net Cash Flow:
$1.43B
1W Performance:
+2.29%
1M Performance:
-1.49%
6M Performance:
+40.52%
1Y Performance:
+29.72%
1-Day Range:
$85.80
$88.87
1-Week Range:
$83.30
$88.87
52-Week Range:
$54.11
$92.59
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
86.04 | 32.47B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
104.89 | 181.50B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.75 | 121.20B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.66 | 113.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.39 | 64.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.60 | 49.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-26 | Initiated | Barclays | Overweight |
| Jun-23-26 | Initiated | Deutsche Bank | Buy |
| May-12-26 | Initiated | The Benchmark Company | Buy |
| Mar-24-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-12-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Initiated | Evercore ISI | In-line |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
Dexcom faces a class action over an alleged data breach that ShinyHunters claimed responsibility for. - Claim Depot
Vaso Stock Surges 149% in a Year: What's Behind the Rally? - TradingView
Vaso Stock Surges 149% in a Year: What's Behind the Rally? - Zacks Investment Research
A Look at DexCom Inc (DXCM) After 5.1% Gain -- GF Value $103.59 vs Price $87.71 - GuruFocus
DexCom gains as NEJM publication boosts Medicare coverage hopes - TradingView
Landmark Dexcom CONNECT Study Published in The New England Journ - GuruFocus
Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin - Dexcom
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Zacks Investment Research
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Yahoo Finance
DexCom (NASDAQ:DXCM): Affordable Growth at a Reasonable Valuation - ChartMill
Here's What to Expect From DexCom’s Next Earnings Report - inkl
DexCom Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
BTIG Adjusts Price Target on DexCom to $96 From $90 - marketscreener.com
DexCom, Inc. (0A4M.L) stock price, news, quote and history - Yahoo Finance UK
DexCom, Inc. (DXCM) options chain – Yahoo Finance - Yahoo Finance Singapore
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Evercore ISI Adjusts Price Target on DexCom to $110 From $90 - marketscreener.com
Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time - www.marketscreener.com
Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time - Yahoo Finance
DexCom Inc (DXCM) Stock Down 4.0% -- Now Undervalued? GF Score: 95/100 - GuruFocus
DexCom Falls as Investors Appear to Take Profits Ahead of Earnings - Quiver Quantitative
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading - Business Wire
Dexcom Launches Largest Dexcom U Program Season Yet, Supporting College Athletes with Diabetes (DXCM) - GuruFocus
DexCom Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
DexCom stock gains 1.22 percent ahead of October earnings - AD HOC NEWS
Continuous Glucose Monitoring Market Size, Share [2026-2034] - Fortune Business Insights
Dexcom Hit With New Lawsuits Over G7 Monitor Failures - Medical Device and Diagnostic industry
DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care - Zacks Investment Research
DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care - TradingView
DexCom (NASDAQ:DXCM): Strong Growth Paired With a High-Quality Technical Setup - ChartMill
DXCM Maintains by RBC Capital -- Price Target Raised to $105 - GuruFocus
ShinyHunters new leak site lists O’Reilly and Dexcom breaches - cybernews.com
DEXCOM INC : RBC RAISES TARGET PRICE TO $105 FROM $90 - Moomoo
ViCentra Presents Large-Scale Real-World Evidence Demonstrating Kaleido Insulin Patch Pump System Delivers Stable Glucose Control with Very Low Hypoglycemia - GlobeNewswire Inc.
RBC Raises Price Target on DexCom to $105 From $90, Keeps Outperform Rating - marketscreener.com
Under a preset trading plan, DexCom (DXCM) EVP Sadie Stern sells 2,565 shares. - Stock Titan
Here's Why DexCom (DXCM) is a Strong Growth Stock - Zacks Investment Research
Why DexCom Could Be the Big Winner Out of Oura’s IPO - Barron's
Dexcom Data Points to a CGM Awareness Gap, and Room to Grow - Medical Product Outsourcing
The Insider Report: The Leaders Have Taken Off - Benzinga
Dexcom Publishes New Report During Easd 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care - marketscreener.com
Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care - Dexcom Investor Relations
Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care - The Joplin Globe
Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care - Business Wire
Dexcom stock slips 2.01 percent ahead of the open - AD HOC NEWS
DexCom (DXCM) Stock Looks Cheap Based On Future Cash Flow - Yahoo Finance
DexCom stock trades below its 52-week high as Truist lifts target - AD HOC NEWS
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dexcom Inc Stock (DXCM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Stern Sadie | EVP Chief People & Culture Off |
Sep 28 '26 |
Sale |
86.15 |
2,565 |
220,975 |
123,478 |
| SADIE STERN | Officer |
Sep 28 '26 |
Proposed Sale |
86.15 |
2,565 |
220,975 |
0 |
| Brown Michael Jon | EVP Chief Legal Compliance Off |
Sep 15 '26 |
Sale |
84.04 |
1,700 |
142,868 |
99,885 |
| AUGUSTINOS NICHOLAS | Director |
Sep 15 '26 |
Sale |
84.04 |
6,539 |
549,538 |
29,293 |
| AUGUSTINOS NICHOLAS | Director |
Sep 15 '26 |
Proposed Sale |
84.04 |
6,539 |
549,538 |
0 |
| MICHAEL BROWN | Officer |
Sep 15 '26 |
Proposed Sale |
84.04 |
1,700 |
142,868 |
0 |
| AUGUSTINOS NICHOLAS | Director |
Sep 14 '26 |
Sale |
84.02 |
1,550 |
130,231 |
35,832 |
| AUGUSTINOS NICHOLAS | Director |
Sep 14 '26 |
Proposed Sale |
84.02 |
1,550 |
130,231 |
0 |
| Sylvain Jereme M | EVP, Chief Financal Officer |
Sep 10 '26 |
Sale |
83.27 |
3,638 |
302,936 |
146,828 |
| JEREME SYLVAIN | Officer |
Sep 10 '26 |
Proposed Sale |
83.27 |
3,638 |
302,936 |
0 |
1.11%
0.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):